Xerostomia Therapeutics Market by Product and Geography - Forecast and Analysis 2021-2025

“The Xerostomia Therapeutics Market study is a comprehensive report with in-depth qualitative and quantitative research evaluating the current scenario and analyzing the growth USD 133.27 million and CAGR of 4% by segment Product and Geography during the forecast period 2019 to 2024” 

Furthermore, this report extensively covers the smart home appliances market segmentation by product (OTC and Prescription) and geography (North America, Europe, Asia, and ROW). The market report also offers information on several market vendors, including Apotex Inc., Church & Dwight Co. Inc., Colgate-Palmolive Co., Cumberland Pharmaceuticals Inc., Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., GlaxoSmithKline Plc, Pharmascience Inc., Quest Products Inc., and Sun Pharmaceutical Industries Ltd.

Download the Report Sample to Unlock the Smart Room Heater Market Size for the Forecast Period and Other Important Statistics 

Parent Market Analysis

Technavio categorizes the Xerostomia Therapeutics Market as a part of the Health Care industry within the Pharmaceuticals industry. Our Technavio research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the forecast year.

Xerostomia Therapeutics Market: Key Drivers, Trends, and Challenges

Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic's impact on the xerostomia therapeutics industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge. 

Key Xerostomia Therapeutics Market Driver

One of the key factors driving growth in the market is the high-risk factors for xerostomia. The most common disease that causes xerostomia is Sjögren’s syndrome, an inflammatory auto-immune disease. Sjögren’s syndrome is characterized by the lymphocytic infiltration of salivary glands, resulting in xerostomia. The high prevalence of Sjögren’s syndrome is the major risk factor for the development of xerostomia. For instance, as per the NIH, Sjögren’s syndrome is a relatively common disorder, and it occurs in 0.1%-4.0% of the general population in the US. Moreover, the growing prevalence of other diseases that can cause xerostomia, such as scleroderma, cystic fibrosis, rheumatoid arthritis, nephritis, systemic lupus erythematosus, hypertension, thyroid dysfunction, diabetes mellitus, endocrine disorders, and cerebral palsy as well as treatments like bone marrow transplants are also major risk factors for the development of xerostomia. Hyposecretory conditions, such as gastritis, pancreatic disorders, and biliary cirrhosis, cause xerostomia. Furthermore, dry mouth is often aggravated by conditions such as hyperventilation, breathing through the mouth, smoking, or drinking alcohol. Dehydration due to the limited intake of water, polyuria, emesis, and diarrhoea can also cause xerostomia. The rising incidence of health conditions or diseases that are high-risk factors for xerostomia is expected to continue to support the growth of the global market during the forecast period. 

Key Xerostomia Therapeutics Market Challenge

The increasing competition from OTC and generic drugs will be a major challenge for the market during the forecast period. Generic medicines are those that contain the same active ingredients and in the same quantity as branded drugs. Therefore, generic medicines have the same effect on the body as branded medicines in terms of their curative powers. The development of generic drugs is simple, less time-consuming, and requires lower R&D expenditure than innovator drugs as the generic versions of innovator drugs do not require pre-clinical and clinical studies. Some companies develop generic versions of innovator drugs and sell them at lower prices than innovator drugs. The number of generic medicines available for the treatment of xerostomia is rising rapidly. For instance, in July 2017, Mylan received the Abbreviated New Drug Application (ANDA) approval from the US FDA for amifostine in 500 mg/vial injection form. Similarly, Cumberland Pharmaceuticals offers Ethyol, or amifostine injection for the treatment of xerostomia, which occurs in patients who receive radiation treatment for head and neck cancer. Therefore, the launch of generic drugs at a lower price than innovator drugs is diminishing and decelerating the growth of the market and is expected to hamper the growth of the global market during the forecast period. 

Xerostomia Therapeutics Market Value Chain Analysis

Our In-house experts produce extensive information on the value chain, and parent market of the market which vendors can leverage to gain a competitive advantage during the forecast period. The Value Chain information provides an end-end understanding of product insight and profit and also optimization and evaluation of business strategies The players across the value chain includes selective data and analysis from entire research findings as per the scope of the report.

Who are the Major Xerostomia Therapeutics Market Vendors?

Apotex Inc. - Cevimeline hydrochloride tablets: It is used for the treatment of dry mouth in patients with Sjogren's syndrome. Under the unified segment, the company offers more than 300 generic pharmaceuticals in approximately 4000 dosages. These include injectables, unit dose products, and speciality products.

The report analyzes the market’s competitive landscape and offers information on several market vendors, including: 

• Apotex Inc.
• Church & Dwight Co. Inc.
• Colgate-Palmolive Co.
• Cumberland Pharmaceuticals Inc.
• Daiichi Sankyo Co. Ltd.
• Eisai Co. Ltd.
• GlaxoSmithKline Plc
• Pharmascience Inc.
• Quest Products Inc.
• Sun Pharmaceutical Industries Ltd.

This statistical study of the market encompasses successful business strategies deployed by the key vendors. The market is fragmented and the vendors are deploying organic and inorganic growth strategies to compete in the market. The market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.

Which are the Key Regions for Xerostomia Therapeutics Market?

For more insights on the market share of various regions Request PDF Sample now!

33% of the market’s growth will originate from North America during the forecast period. US and Canada are the key markets for xerostomia therapeutics in North America. Market growth in this region will be slower than the growth of the market in other regions.

North America was the leader in the global market in terms of market share in 2018. This is mainly attributed to the growing geriatric population as well as the increasing prevalence of xerostomia-associated diseases in the US. For instance, the old-age dependency ratio or the ratio that measures the number of retired people to the number of working people has seen a significant rise in recent years and is expected to have a similar growth rate in the coming years in the US. The increase in the old-age dependency ratio is also an indicator of the rising geriatric population in the US. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.

What are the Revenue-generating Product Segments in the Xerostomia Therapeutics Market?

To gain further insights on the market contribution of various segments Request a PDF Sample

The market share growth by the OCT segment will be significant during the forecast period. The growth of the OTC segment is expected to be further driven by the recent approvals of OTC therapeutics. For instance, in May 2018, Prisyna, the oral care division of Synedgen, announced that it had received approval from the US Food and Drug Administration (FDA) to market Moisyn products for the treatment of xerostomia. Similarly, in November 2016, OraCoat, a division of ORAHEALTH, launched a new version of OraCoat and XyliGel to relieve the symptoms of xerostomia for people who had very low levels of saliva. Thus, these recent product approvals for the treatment of xerostomia are expected to lead to revenue generation in the segment and eventually augment the growth of the OTC segment during the forecast period.

This report provides an accurate prediction of the contribution of all the segments to the growth of the market size and actionable market insights on the post-COVID-19 impact on each segment.

Request PDF sample

What are the Key Data Covered in this Xerostomia Therapeutics Market Report?

• CAGR of the market during the forecast period 2020-2024
• Detailed information on factors that will drive market growth during the next five years
• Precise estimation of the market size and its contribution to the parent market
• Accurate predictions on upcoming trends and changes in consumer behaviour
• The growth of the xerostomia therapeutics industry across North America, Europe, Asia, and ROW
• A thorough analysis of the market’s competitive landscape and detailed information on vendors
• Comprehensive details of factors that will challenge the growth of market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch